BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.76% | -28.02% | 12.75% | 24.10% | 28.81% |
| Total Depreciation and Amortization | -31.22% | -18.88% | -12.18% | -0.21% | -8.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.77% | 31.87% | -28.81% | -66.28% | -38.99% |
| Change in Net Operating Assets | 3,812.33% | -66.85% | -153.57% | -162.03% | -109.46% |
| Cash from Operations | 10.28% | -96.64% | -20.19% | -4.21% | 26.44% |
| Capital Expenditure | -17.39% | -230.77% | -733.33% | 23.81% | 45.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -17.39% | -230.77% | -733.33% | 23.81% | 45.24% |
| Total Debt Issued | 5.88% | 0.00% | 321.86% | -19.22% | -39.68% |
| Total Debt Repaid | 21.82% | -58.87% | -131.18% | -41.51% | -30.22% |
| Issuance of Common Stock | -41.39% | 91.73% | 38.50% | 89.42% | 30.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -44.57% | 72.11% | 50.75% | 70.25% | -9.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -226.08% | -1,777.97% | 82.16% | 126.32% | 546.96% |